Why UK Patients Choose EverydayMeds for Weight Management
What's Better Mounjaro or Wegovy: GPhC Pharmacy Expert Analysis
When comparing what's better between Mounjaro or Wegovy, the fundamental difference lies in their active compounds and receptor targets. Wegovy (semaglutide) acts solely on GLP-1 receptors, whilst Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors as a dual agonist. Both are prescription-only medicines requiring clinical assessment through our GPhC-registered pharmacy (#9012878). Neither treatment can be declared universally "better" as effectiveness depends on individual patient factors including medical history, current medications, and treatment response.
At EverydayMeds, our Leicester-based pharmacy provides both treatments with identical clinical oversight and regulatory standards. Licensed UK prescribers review every consultation to determine suitability, ensuring patients receive the most appropriate treatment based on MHRA-approved indications. Both medications require administration alongside a reduced-calorie diet and increased physical activity for optimal effectiveness, with regular monitoring throughout treatment.
Wegovy vs Mounjaro Pricing: Transparent UK Pharmacy Costs
Understanding what's better between Mounjaro or Wegovy often involves cost considerations alongside clinical factors. Wegovy pricing at our GPhC-registered facility starts with 0.25mg at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to maintenance 2.4mg (£209.99). New customers apply code FIRST40 at checkout, whilst returning patients use DOSE25 to access these competitive rates. Our Getting Started bundles provide convenient dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99.
Mounjaro pricing follows a different structure due to its distinct formulation and dosing schedule. Both treatments represent significant investments in long-term weight management, with costs varying based on individual dose requirements and treatment duration. Our clinical team provides transparent cost discussions during consultation, ensuring patients understand the financial commitment before starting either prescription-only medicine.
Clinical Evidence: What's Better Mounjaro or Wegovy Research
Clinical trials provide objective data when determining what's better between Mounjaro or Wegovy for individual patients. Wegovy's STEP trials demonstrated substantial weight management benefits, with STEP 1 showing approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events amongst patients with established cardiovascular disease.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual-receptor mechanism, though direct head-to-head comparisons between the treatments remain limited due to different trial designs and patient populations. Both studies demonstrate efficacy when used alongside lifestyle interventions, though individual responses vary significantly based on patient-specific factors assessed during clinical consultation.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1 produced in the intestines. This mechanism reduces appetite by acting on brain centres controlling hunger and satiety, helping patients feel fuller after consuming smaller portions. The medication also slows gastric emptying, prolonging the feeling of fullness between meals. Semaglutide may reduce food cravings and the reward response to high-calorie foods, supporting long-term dietary adherence. Weekly administration via the FlexTouch pen provides consistent medication levels, requiring dose escalation from 0.25mg through to 2.4mg maintenance over 16 weeks. The prescription-only medicine works most effectively when combined with structured lifestyle modifications including dietary changes and increased physical activity.
EverydayMeds Ordering Process: What's Better Mounjaro or Wegovy Assessment
Determining what's better between Mounjaro or Wegovy begins with our comprehensive 3-minute online clinical assessment covering medical history, current medications, weight management goals, and treatment preferences. Licensed UK prescribers review each consultation within 3 working days (standard service) or 24 hours (express option), evaluating suitability for either treatment based on MHRA-approved criteria. Once prescribed, medications are dispatched via next-day cold-chain delivery from our Leicester facility, maintaining the 2-8°C temperature requirements throughout transit. Our GPhC registration (#9012878) ensures full compliance with pharmaceutical regulations, whilst ongoing clinical support addresses any questions during treatment. Patients receive detailed administration guidance, dose escalation schedules, and direct access to our clinical team for treatment optimisation.
Storage and Practical Considerations: Mounjaro vs Wegovy Differences
When evaluating what's better between Mounjaro or Wegovy, practical storage differences may influence treatment choice. Wegovy FlexTouch pens require refrigeration at 2-8°C before first use but can remain at room temperature (below 30°C) for up to 6 weeks once removed from the fridge. Mounjaro pens also require refrigeration but only maintain stability for 21 days at room temperature, making Wegovy more convenient for extended travel or variable storage situations. Both are single-use pens requiring weekly administration, though dose escalation schedules differ between the two prescription-only medicines. The FlexTouch design provides consistent dose delivery with clear dosing windows, whilst both treatments require proper sharps disposal following local council guidelines. Storage flexibility often becomes a decisive factor for patients with active lifestyles or frequent travel commitments.
Regulatory Compliance: Why GPhC Registration Matters for Wegovy
Understanding what's better between Mounjaro or Wegovy extends beyond clinical efficacy to regulatory compliance and pharmacy legitimacy. EverydayMeds operates under GPhC registration #9012878, providing full transparency through the pharmacyregulation.org searchable database. This registration ensures adherence to strict pharmaceutical standards including prescriber verification, medication authenticity, and proper storage protocols. Our Leicester-based facility maintains MHRA-compliant supply chains with full audit trails for both treatments, protecting patients from counterfeit or improperly stored medications prevalent in unregulated online sources.
Both Wegovy and Mounjaro carry Black Triangle (▼) status indicating additional MHRA monitoring for safety profile development. Licensed UK prescribers within our network complete ongoing professional development specific to weight management treatments, ensuring current knowledge of contraindications, drug interactions, and monitoring requirements. This regulatory framework provides essential patient safety protections often absent from overseas or unregistered pharmacy operations.
Start Your Weight Management Journey: Mounjaro or Wegovy Selection
Rather than determining what's better between Mounjaro or Wegovy in isolation, our clinical approach focuses on matching treatment characteristics to individual patient needs and preferences. Both treatments are available through our secure online consultation platform, with new customers using code FIRST40 and returning patients applying DOSE25 at checkout for competitive pricing. Our prescribers consider medical history, current medications, lifestyle factors, and treatment goals when recommending either semaglutide or tirzepatide therapy. The 3-minute assessment initiates a comprehensive clinical review ensuring appropriate treatment selection based on MHRA-approved indications. Begin your consultation today through our GPhC-registered pharmacy to discover which prescription-only medicine aligns with your weight management objectives and clinical profile.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
